Literature DB >> 15880435

Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe.

Freddie Bray1, Anja H Loos, Mariet Oostindier, Elisabete Weiderpass.   

Abstract

Corpus uteri cancer is the fourth most common neoplasm in women in Europe and the tenth most common cause of cancer death. We examined geographic and temporal variations in corpus uteri cancer incidence and mortality rates in the age groups 25-49 and 50-74 in 22 European countries. The disease is considerably less common in premenopausal women, with incidence and mortality rates decreasing throughout Europe and mortality declines more marked in western and southern European countries. Incidence rates among postmenopausal women are highest in the Czech Republic, Slovakia, Sweden and Slovenia and lowest in France and the United Kingdom. Increasing incidence trends in this age group are observed in the Nordic countries (except Denmark) and in the United Kingdom. Some increases are also seen in eastern (Slovakia) and southern Europe (Spain and Slovenia), while relatively stable or modestly decreasing trends are observed in Italy and most western European countries. Postmenopausal mortality rates are systematically higher in eastern Europe, with death rates in the Ukraine, Latvia, Czech Republic, Russia and Belarus 2-3 times those seen in western Europe. Declining mortality trends are seen in most populations, though in certain Eastern European countries, the declines began rather recently, during the 1980s. In Belarus and Russia, recent postmenopausal death rates are stable or increasing. The rates are adjusted for misclassification of uterine cancer deaths but remain unadjusted for hysterectomy, and where there is an apparent levelling off of incidence or mortality rates recently, rising prevalence of hysterectomy cannot be discounted as an explanation. However, the trends by age group can be viewed in light of several established risk factors for endometrial cancer that are highly prevalent and most likely changing with time. These are discussed, as are the prospects for preventing the disease. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15880435     DOI: 10.1002/ijc.21099

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Polymorphisms in cyclooxygenase-2 gene in endometrial cancer patients.

Authors:  Federica Torricelli; Vincenzo Dario Mandato; Enrico Farnetti; Martino Abrate; Bruno Casali; Gino Ciarlini; Debora Pirillo; Maria Carolina Gelli; Luigi Costagliola; Davide Nicoli; Stefano Palomba; Giovanni Battista La Sala
Journal:  Tumour Biol       Date:  2015-04-22

2.  Rectal bleeding after radiation therapy for endometrial cancer.

Authors:  Devarati Mitra; Remi Nout; Paul J Catalano; Carien Creutzberg; Nicole Cimbak; Larissa Lee; Akila N Viswanathan
Journal:  Radiother Oncol       Date:  2015-05-20       Impact factor: 6.280

3.  Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review.

Authors:  Mei-Yi Li; Xiao-Xia Hu; Jian-Hong Zhong; Lu-Lu Chen; Yong-Xiu Lin
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

4.  Prognostic Impact of ABO Blood Group on Type I Endometrial Cancer Patients- Results from Our Own and Other Studies.

Authors:  Vincenzo Dario Mandato; Federica Torricelli; Valentina Mastrofilippo; Gino Ciarlini; Debora Pirillo; Enrico Farnetti; Loretta Fornaciari; Bruno Casali; Maria Carolina Gelli; Martino Abrate; Lorenzo Aguzzoli; Giovanni Battista La Sala; Davide Nicoli
Journal:  J Cancer       Date:  2017-08-23       Impact factor: 4.207

Review 5.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

6.  Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Mark McEvoy; John Attia; Rodney J Scott
Journal:  BMC Cancer       Date:  2010-07-21       Impact factor: 4.430

7.  Aqueous Extract of Solanum nigrum Leaf Activates Autophagic Cell Death and Enhances Docetaxel-Induced Cytotoxicity in Human Endometrial Carcinoma Cells.

Authors:  Cheng-Jeng Tai; Chien-Kai Wang; Yu-Jia Chang; Chi-Shian Lin; Chen-Jei Tai
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-08       Impact factor: 2.629

8.  Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Naomi E Allen; Timothy J Key; Laure Dossus; Sabina Rinaldi; Anne Cust; Annekatrin Lukanova; Petra H Peeters; N Charlotte Onland-Moret; Petra H Lahmann; Franco Berrino; Salvatore Panico; Nerea Larrañaga; Guillem Pera; Maria-José Tormo; Maria-José Sánchez; J Ramón Quirós; Eva Ardanaz; Anne Tjønneland; Anja Olsen; Jenny Chang-Claude; Jakob Linseisen; Mandy Schulz; Heiner Boeing; Eva Lundin; Domenico Palli; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Sheila Bingham; Kay-Tee Khaw; H Bas Bueno-de-Mesquita; Antonia Trichopoulou; Dimitiros Trichopoulos; Androniki Naska; Rosario Tumino; Elio Riboli; Rudolf Kaaks
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

9.  Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα.

Authors:  Binya Liu; Qi Che; Haifeng Qiu; Wei Bao; Xiaoyue Chen; Wen Lu; Bilan Li; Xiaoping Wan
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  The incidence rate of corpus uteri cancer among females in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001-2008.

Authors:  Ibrahim G Alghamdi; Issam I Hussain; Mohamed S Alghamdi; Mohamed A El-Sheemy
Journal:  Int J Womens Health       Date:  2014-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.